Cargando…

Cost-effectiveness of first-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy

OBJECTIVE: To assess the cost-effectiveness of erlotinib versus supportive care (placebo) overall and within a predefined rash subgroup in elderly patients with advanced non-small-cell lung cancer who are unfit for chemotherapy and receive only active supportive care due to their poor performance st...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khan, Iftekhar, Morris, Stephen, Hackshaw, Allan, Lee, Siow-Ming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2015
Materias:	Health Economics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4499745/ https://www.ncbi.nlm.nih.gov/pubmed/26137881 http://dx.doi.org/10.1136/bmjopen-2014-006733

Ejemplares similares

First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial
por: Lee, Siow Ming, et al.
Publicado: (2012)

Cost-effectiveness analysis of adding ramucirumab to the first-line erlotinib treatment for untreated EGFR-mutated metastatic non-small cell lung cancer in China
por: Liu, Qiao, et al.
Publicado: (2020)

Cost-effectiveness analysis of adding transarterial chemoembolisation to lenvatinib as first-line treatment for advanced hepatocellular carcinoma in China
por: Li, Wei, et al.
Publicado: (2023)

Cost-effectiveness analysis of cetuximab combined with chemotherapy as a first-line treatment for patients with RAS wild-type metastatic colorectal cancer based on the TAILOR trial
por: Wang, Huijuan, et al.
Publicado: (2020)

Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USA
por: Zeng, Xiaohui, et al.
Publicado: (2019)

Societal costs of chemotherapy in the UK: an incidence-based cost-of-illness model for early breast cancer
por: Parsekar, Krishnali, et al.
Publicado: (2021)

Cost-effectiveness analysis of serplulimab combined with chemotherapy in the treatment of extensive-stage small-cell lung cancer from the perspective of the healthcare system in China
por: Long, Yunchun, et al.
Publicado: (2023)

Camrelizumab in patients with advanced non-squamous non-small cell lung cancer: a cost-effective analysis in China
por: Xie, Qian, et al.
Publicado: (2022)

Cost of elective percutaneous coronary intervention in Malaysia: a multicentre cross-sectional costing study
por: Lee, Kun Yun, et al.
Publicado: (2017)

Half-dose fulvestrant plus anastrozole as a first-line treatment for hormone receptor-positive metastatic breast cancer: a cost-effectiveness analysis
por: Huang, Xiaoting, et al.
Publicado: (2020)

Protocol for the cost-effectiveness of parenteral iron and oral iron therapy for first-line management of anaemia among pregnant women in a natural programme setting in Gujarat
por: Saha, Somen, et al.
Publicado: (2021)

Stopping clinical trials early for futility: retrospective analysis of several randomised clinical studies
por: Jitlal, Mark, et al.
Publicado: (2011)

The clinical role of VeriStrat testing in patients with advanced non–small cell lung cancer considered unfit for first-line platinum-based chemotherapy()
por: Lee, Siow Ming, et al.
Publicado: (2019)

Cost-utility and budget impact analyses of the use of NEPA for chemotherapy-induced nausea and vomiting prophylaxis in Italy
por: Restelli, Umberto, et al.
Publicado: (2017)

Trends in unsuitability for blood donation in the Brazilian Amazon
por: Rivera Chavez, Graciela Marleny, et al.
Publicado: (2022)

Cost-effectiveness of a European preventive cardiology programme in primary care: a Markov modelling approach
por: Mistry, Hema, et al.
Publicado: (2012)

Monetary costs of agitation in older adults with Alzheimer's disease in the UK: prospective cohort study
por: Morris, Stephen, et al.
Publicado: (2015)

Tislelizumab plus chemotherapy is more cost-effective than chemotherapy alone as first-line therapy for advanced non-squamous non-small cell lung cancer
por: Liang, Xueyan, et al.
Publicado: (2023)

Prolonged response to first-line erlotinib for advanced lung adenocarcinoma
por: Copeman, Michael
Publicado: (2008)

Cost-effectiveness of a community-delivered multicomponent intervention compared with enhanced standard care of obese adolescents: cost-utility analysis alongside a randomised controlled trial (the HELP trial)
por: Panca, Monica, et al.
Publicado: (2018)

Role of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer
por: Reguart, Noemí, et al.
Publicado: (2010)

A mixed treatment comparison of Erlotinib vs. placebo and Erlotinib vs. Geftinib using Bayesian approaches
por: Khan, Iftekhar, et al.
Publicado: (2013)

Cost-effectiveness analysis of camrelizumab plus chemotherapy as first-line treatment for advanced squamous NSCLC in China
por: Shao, Taihang, et al.
Publicado: (2022)

Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer
por: Isla, Dolores, et al.
Publicado: (2016)

Cost-effectiveness of habit-based advice for weight control versus usual care in general practice in the Ten Top Tips (10TT) trial: economic evaluation based on a randomised controlled trial
por: Patel, Nishma, et al.
Publicado: (2018)

Effectiveness and cost-effectiveness of a cardiovascular risk prediction algorithm for people with severe mental illness (PRIMROSE)
por: Zomer, Ella, et al.
Publicado: (2017)

Gemcitabine Combined with Capecitabine Compared to Gemcitabine with or without Erlotinib as First-Line Chemotherapy in Patients with Advanced Pancreatic Cancer
por: Lim, Jae Yun, et al.
Publicado: (2015)

Cost-effectiveness analysis of implementing an integrated neonatal care kit to reduce neonatal infection in rural Pakistan
por: Muttalib, Fiona, et al.
Publicado: (2022)

Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients
por: Kim, Lucia, et al.
Publicado: (2017)

Cost-effectiveness analysis of first-line serplulimab combined with chemotherapy for extensive-stage small cell lung cancer
por: Liang, Xueyan, et al.
Publicado: (2023)

A systematic review of the cost and cost-effectiveness of electronic discharge communications
por: Sevick, Laura K, et al.
Publicado: (2017)

Neratinib plus capecitabine versus lapatinib plus capecitabine as the third-line therapy for HER2-positive metastatic breast cancer in China: a cost-effectiveness analysis
por: Wu, Yue, et al.
Publicado: (2022)

Observational retrospective study calculating health service costs of patients receiving surgery for chronic rhinosinusitis in England, using linked patient-level primary and secondary care electronic data
por: Clarke, Caroline S, et al.
Publicado: (2022)

Decreasing rates of cost-related medication non-adherence by age advancement among American generational cohorts 2004–2014: a longitudinal study
por: Zhang, James, et al.
Publicado: (2022)

Can we reduce costs and prevent more unintended pregnancies? A cost of illness and cost-effectiveness study comparing two methods of EHC
por: Thomas, Christine M, et al.
Publicado: (2013)

Sports-related traumatic brain injuries and acute care costs in children
por: Singh, Sonia, et al.
Publicado: (2023)

Economic impact of the first pass effect in mechanical thrombectomy for acute ischaemic stroke treatment in Spain: a cost-effectiveness analysis from the national health system perspective
por: González Diaz, Eva, et al.
Publicado: (2022)

Randomized Trial of Erlotinib Plus Whole-Brain Radiotherapy for NSCLC Patients With Multiple Brain Metastases
por: Lee, Siow Ming, et al.
Publicado: (2014)

Costs of surgical procedures in Indian hospitals
por: Chatterjee, Susmita, et al.
Publicado: (2013)

End-stage renal disease—financial costs and years of life lost in Panama: a cost-analysis study
por: Moreno Velásquez, Ilais, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_mtpqpgpekvlp7mdlnb54chrsmj